FOI release

Drug trial SAEs

Some or all of the information requested may not have been provided because we required clarification from the requester.

Case reference FOI2025/01286

Received 10 December 2025

Published 2 February 2026

Request

Is it possible to request the SAEs that have been reported for a current drug trial being carried out byAstra Zeneca? Official Study Title: A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination with Carboplatin plus Pemetrexed Versus Platinum plus Pemetrexed or Nivolumab plus Ipilimumab in Participants with Unresectable Pleural Mesothelioma (eVOLVE-Meso) Study number: D7988C00001 Product name: Volrustomig (MEDI5752)

Response

See attached

Documents

• FOI2025_01286 (redacted).pdf (614.1 KB)

This is Medicines and Healthcare products Regulatory Agency's response to a freedom of information (FOI) or environmental information regulations (EIR) request.

You can browse our other responses or make a new FOI request.